The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESH AL 2026 | Why TP53-mutated AML is so therapeutically challenging: an insight into disease biology
Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, shares insights into the outcomes of patients with TP53-mutated acute myeloid leukemia (AML), highlighting the heterogeneity of this disease due to diverse mutation subtypes, variants, and regulators. This interview took place at the 5th How to Diagnose and Treat: Acute Leukemias meeting of the European School of Hematology (ESH AL) in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
During the ESH meeting, I presented and discussed about the TP53-mutated myeloid malignancies. As we know today, this is a specific subgroup of patients with a very poor outcome. What we can say about this specific setting is that this disease is very heterogeneous because today we know that there are several subtypes of TP53 mutation. There are also several subtypes of variant and there are also several subtypes of regulators around TP53 that could have an impact on the function of TP53, but also of the level of the expression of p53 protein...
During the ESH meeting, I presented and discussed about the TP53-mutated myeloid malignancies. As we know today, this is a specific subgroup of patients with a very poor outcome. What we can say about this specific setting is that this disease is very heterogeneous because today we know that there are several subtypes of TP53 mutation. There are also several subtypes of variant and there are also several subtypes of regulators around TP53 that could have an impact on the function of TP53, but also of the level of the expression of p53 protein. So at the end it could have an impact also on the prognosis of the disease. So today we know that there is a single-hit mutation and multi-hit mutation. We know that the very poor prognosis is associated to the multi-hit mutation. And today, unfortunately, all the usual treatments failed to improve the outcome of these patients with treatment with intensive chemo or non-intensive chemo, we could obtain only 40% of response and only five months of median overall survival.
Read more...
Disclosures
Abbvie, BMS, Novartis, Servier, Gilead, Jazz Pharma
